Logo

American Heart Association

  27
  0


Final ID: Sa2033

Chronic Kidney Disease with Inflammation and Incident Coronary Heart Disease in Black Adults from the Jackson Heart Study

Abstract Body (Do not enter title and authors here): Background:
Inflammation and chronic kidney disease (CKD) increase the risk of coronary heart disease (CHD), which disproportionately affects Black adults. However, it remains unclear whether the coexistence of inflammation and CKD confers a greater risk than either condition alone.
Research Question:
Does the coexistence of inflammation and CKD confer a higher risk of incident CHD compared to either condition alone?
Methods:
We included baseline data (2000–2004) from Jackson Heart Study participants with available measurements of inflammation, defined as high-sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L, and chronic kidney disease (CKD), defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 (CKD 2021 EPI equation), and without CHD. Participants were classified into four groups: no CKD and no inflammation (reference group), inflammation without CKD, CKD without inflammation, and CKD with inflammation and followed through 2016 for incident CHD. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident CHD events defined as adjudicated probable or definite myocardial infarction (MI), fatal MI, or a history of cardiac procedures including percutaneous coronary intervention or coronary artery bypass grafting. The fully adjusted model included covariates for age, sex, systolic blood pressure, antihypertensive medications, diabetes, smoking, alcohol, physical activity, statins, total cholesterol, LDL-C, and HDL-C.
Results:
Among 4,073 participants (mean age 53.9±12.8 years; 64.3% women), 2,140 (52.5%) had no CKD and no inflammation, 1,761 (43.2%) had inflammation without CKD, 66 (1.6%) had CKD without inflammation, and 106 (2.6%) had CKD with inflammation. Over a median follow-up of 13.8 years, the unadjusted models showed that CHD risk was highest in the CKD with inflammation group (HR 5.53, 95% CI 3.52–8.68). Risk was also elevated in those with CKD without inflammation (HR 2.29, 95% CI 1.01–5.22), but not in those with inflammation without CKD (HR 1.15, 95% CI 0.87–1.52). After adjustment for covariates, only the CKD with inflammation group remained significantly associated with incident CHD (HR 2.45, 95% CI 1.53–3.92).
Conclusion:
Black adults with concomitant inflammation and CKD have a significantly higher risk of incident CHD compared to those with either condition alone, highlighting the need for intensive management and the potential role of novel anti-inflammatory therapies.
  • Khan, Laibah  ( University of Mississippi Med CT , Jackson , Mississippi , United States )
  • Butler, Javed  ( Baylor Scott and White Research , Dallas , Texas , United States )
  • Hall, Michael  ( University of Mississippi Med CT , Jackson , Mississippi , United States )
  • Yimer, Wondwosen  ( University of Mississippi Med CT , Jackson , Mississippi , United States )
  • Javaid, Syed Sarmad  ( University of Mississippi Med CT , Jackson , Mississippi , United States )
  • Hamid, Arsalan  ( Baylor College of Medicine , Houston , Texas , United States )
  • Young, Bessie  ( University of Washington , Seattle , Washington , United States )
  • Blaha, Michael  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
  • Defilippis, Andrew  ( Vanderbilt University Medical Cente , Nashville , Tennessee , United States )
  • Tio, Maria Clarissa  ( University of Mississippi Med CT , Jackson , Mississippi , United States )
  • Kamimura, Daisuke  ( Yokohama City University Medical Center , Yokohoma , Japan )
  • Author Disclosures:
    Laibah Khan: DO NOT have relevant financial relationships | Javed Butler: DO have relevant financial relationships ; Consultant:Abbott :Active (exists now) ; Consultant:Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillent, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultromic, Vera, Zoll:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) ; Consultant:CVRx:Active (exists now) ; Consultant:CSL Vifor:Active (exists now) ; Consultant:Cardior:Active (exists now) ; Consultant:Cardiac Dimension:Active (exists now) ; Consultant:Bristol Myers Squibb:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:AskBio:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:American Regent:Active (exists now) ; Consultant:Adaptyx:Active (exists now) | Michael Hall: DO have relevant financial relationships ; Consultant:OrthoClinical Diagnostics:Active (exists now) ; Consultant:Currax:Active (exists now) | Wondwosen Yimer: DO NOT have relevant financial relationships | Syed Sarmad Javaid: DO NOT have relevant financial relationships | Arsalan Hamid: DO NOT have relevant financial relationships | Bessie Young: No Answer | Michael Blaha: DO have relevant financial relationships ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Consultant:Eli Lilly:Past (completed) ; Consultant:Boehringer Ingelheim:Past (completed) ; Consultant:Astra Zeneca:Past (completed) ; Consultant:New Amsterdam:Active (exists now) ; Consultant:Agepha:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Idorsia:Past (completed) ; Consultant:Genentech:Past (completed) ; Consultant:Bayer:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Active (exists now) | Andrew DeFilippis: DO have relevant financial relationships ; Consultant:Velakor Biotherapeutics:Past (completed) ; Consultant:TigerMed:Past (completed) ; Consultant:NovoNordisk:Past (completed) | Maria Clarissa Tio: No Answer | Daisuke Kamimura: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Kidney Health as a Determinant of Cardiovascular Health: Risk, Outcome Trends and Therapeutic Approaches

Saturday, 11/08/2025 , 10:30AM - 11:30AM

Abstract Poster Board Session

More abstracts on this topic:
A novel reproducible low-cost model of acute myocardial infarction in swine

Li Yichen, Zheng Zilong, Tang Weijie, Chen Wangping, Yang Jinfu, Fan Chengming

Cardiorenal Interaction Assessment via ECG Features: A Study using Dynamic Time Warping and Extracted Feature Clustering

Zhao Sally, Adhin Bhavna, Zhan Ye, Fisch Sudeshna

More abstracts from these authors:
Association of Inflammatory Hypertension with Left Ventricular Hypertrophy in Black Adults from the Genetic Epidemiology Network of Arteriopathy Study

Khan Laibah, Hall Michael, Lirette Seth, Javaid Syed Sarmad, Windham B Gwen, Kullo Iftikhar, Butler Kenneth, Mace Hunter, Blaha Michael, Butler Javed

Associations Between Chronic Kidney Disease and Inflammatory Biomarkers in the Genetic Epidemiology Network of Arteriopathy Cohort

Javaid Syed Sarmad, Hall Michael, Lirette Seth, Khan Laibah, Windham B Gwen, Kullo Iftikhar, Rule Andrew, Butler Kenneth, Tio Maria Clarissa, Butler Javed

You have to be authorized to contact abstract author. Please, Login
Not Available